Physician profile
Gerald Grodstein
NPI 1245211440
$7,134.01
in general payments reported to CMS, 2019-2025
32 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $1,698 · 2021: $122 · 2022: $198 · 2023: $956 · 2024: $1,330 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606 · Travel and Lodging: $111 · Education: $86.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,605.73 |
| Travel and Lodging | $111.39 |
| Education | $86.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,772.69 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $713.54 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $530.22 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $528.11 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $515.79 | 2022-2025 | |
| Ardelyx, INC. | $386.93 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Fresenius USA Marketing, INC. | $347.60 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Travere Therapeutics, INC. | $261.35 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $255.82 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $245.30 | 2023-2025 | |
| Novo Nordisk INC | $240.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Vifor Pharma, INC. | $192.14 | 2019-2024 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $150.00 | 2024-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $130.63 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $126.80 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $124.99 | 2019 | |
| Genentech USA, INC. | $118.31 | 2019 | |
| Organox LTD | $111.39 | 2025 | |
| Glaxosmithkline, LLC. | $92.90 | 2022-2024 | Benlysta, Shingrix, Jesduvroq |
| Janssen Pharmaceuticals, INC | $59.54 | 2019 | |
| Lilly USA, LLC | $56.50 | 2023-2024 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $25.33 | 2019-2020 | |
| Renalytix Ai, INC. | $17.90 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ani Pharmaceuticals, INC. | $17.33 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.27 | 2023 | Jardiance, Tradjenta |
| Sanofi Pasteur INC. | $15.44 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.91 | 2023 | Keveyis |
| Mallinckrodt Enterprises LLC | $14.35 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.86 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.80 | 2020 | |
| Merck Sharp & Dohme LLC | $12.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Grodstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.